MedTrace Logo

A Study of Mosliciguat in PH-ILD

NCT06635850 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2026-02-20

No results posted yet for this study

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Conditions

Interventions

DRUG

Mosliciguat

Dose level 1, 2, or 3 for inhalation

DEVICE

Dry Powder Inhaler

Dry powder inhaler for mosliciguat or placebo delivery

DRUG

Placebo

Matching placebo for inhalation

Sponsors & Collaborators

  • Pulmovant, Inc.

    lead INDUSTRY

Principal Investigators

  • Ubaldo Martin, MD · Pulmovant, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-29
Primary Completion
2026-12-31
Completion
2028-01-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06635850 on ClinicalTrials.gov